PlainPharmaWatch

CMS Open Payments · Tool

GRT US Holding, Inc. vs ONY Biotech Inc.

Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.

A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.

Compare Different Companies

vs

Relationship comparison

Which recorded payment profile is more concentrated?

GRT US Holding, Inc. has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 5,103, versus 3,464 for the other company. Its single largest recorded recipient represents 65.8% of that company's General Payments recipient total.

HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.

GRT US Holding, Inc.
HHI 5,103 · top recipient 65.8%
Ranked #342 of 1,838 companies by HHI
ONY Biotech Inc.
HHI 3,464 · top recipient 55.1%
Ranked #506 of 1,838 companies by HHI

Payment Overview

Total Payments
$40.0K
% of Industry
0.0%
Transactions
18
Avg per Transaction
$2.2K
Recipients
15
Avg per Recipient
$2.7K
Payment Types
4
Top Payment Type
Honoraria
Company B

ONY Biotech Inc.

Total Payments
$39.6K
% of Industry
0.0%
Transactions
43
Avg per Transaction
$921.87
Recipients
43
Avg per Recipient
$921.87
Payment Types
4
Top Payment Type
Compensation for Services Other Than Consulting

Highlighted values indicate the higher figure for each metric.

Total payments compared

GRT US Holding, Inc. vs ONY Biotech Inc. - total reported payments in CMS Open Payments PY2024

GRT US Holding, Inc.$40.0KONY Biotech Inc.$39.6K

General Payment Types Breakdown

Category shares use each company's General Payments total, not the all-tracks (General + Research + Ownership) hero figure.

GRT US Holding, Inc.

Honoraria $17.0K

52.6%

Travel and Lodging $9.5K

29.4%

Compensation for Services Other Than Consulting $4.9K

15.1%

Food and Beverage $952.27

2.9%

ONY Biotech Inc.

Compensation for Services Other Than Consulting $24.9K

62.8%

Consulting Fee $12.6K

31.8%

Food and Beverage $1.6K

4.1%

Gift $466.25

1.2%

Top 5 General-Payment Recipients

This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.

GRT US Holding, Inc.

  1. 1

    MORGAN JONES

    $21,292.53 · 6 txns

  2. 2

    TIMOTHY MCALINDON

    $8,861.75 · 4 txns

  3. 3

    OSCAR DELEON CASASOLA

    $1,590.00 · 1 txns

  4. 4

    PATRICK BURGE

    $202.04 · 1 txns

  5. 5

    RAYMOND BRICKHOUSE

    $202.04 · 1 txns

ONY Biotech Inc.

  1. 1

    GEORGE ALBERT

    $21,851.88 · 9 txns

  2. 2

    SCOTT GUTHRIE

    $4,900.24 · 6 txns

  3. 3

    DINUSHAN KALUARACHCHI

    $4,315.82 · 6 txns

  4. 4

    KARI ROBERTS

    $4,252.31 · 6 txns

  5. 5

    ERICK GERDAY

    $2,200.00 · 1 txns

Summary Comparison

Metric GRT US Holding, Inc. ONY Biotech Inc.
Total Payments $40.0K $39.6K
% of Industry Total 0.0% 0.0%
Transaction Count 18 43
Avg per Transaction $2.2K $921.87
Recipient Count 15 43
Avg per Recipient $2.7K $921.87
Payment Type Count 4 4
Top Payment Type Honoraria Compensation for Services Other Than Consulting

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.